Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors

NCT04450732 is registered in ClinicalTrials.gov with GeneQuantum Healthcare (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT04450732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04450732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors
Lead sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 7, 2020
Completion date
May 1, 2024
Enrollment
96 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive advanced solid tumor, her2-positive biliary tract cancer, her2-positive breast cancer, her2-positive salivary gland carcinomas